BenevolentAI Atopic Dermatitis Drug Fails To Deliver
Trk Inhibitor Does Not Significantly Reduce Itch and Inflammation
The UK artificial intelligence drug development expert has reported disappointing findings from a Phase II trial of lead candidate BEN-2293 in atopic dermatitis.
